Stephen Pakola's most recent trade in Regenxbio Inc was a trade of 2,161 Common Stock done at an average price of $7.9 . Disclosure was reported to the exchange on July 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.86 per share. | 02 Jul 2026 | 2,161 | 215,170 (0%) | 0% | 7.9 | 16,985 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2026 | 2,161 | 64,812 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.64 per share. | 02 Jul 2026 | 2,161 | 213,009 (0%) | 0% | 13.6 | 29,476 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2026 | 36,725 | 66,973 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.86 per share. | 29 Jun 2026 | 36,725 | 213,009 (0%) | 0% | 12.9 | 472,284 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.86 per share. | 29 Jun 2026 | 36,725 | 249,734 (0%) | 0% | 7.9 | 288,659 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.04 per share. | 29 Jun 2026 | 19,608 | 213,009 (0%) | 0% | 11.0 | 216,472 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.02 per share. | 11 May 2026 | 15,309 | 232,617 (0%) | 0% | 11.0 | 168,705 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.35 per share. | 10 Mar 2026 | 5,124 | 247,926 (0%) | 0% | 10.3 | 53,033 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.16 per share. | 01 Feb 2026 | 5,267 | 253,050 (0%) | 0% | 11.2 | 58,780 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 65,847 | 258,317 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 35,402 | 35,402 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.40 per share. | 02 Jan 2026 | 18,247 | 192,470 (0%) | 0% | 14.4 | 262,757 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.07 per share. | 01 Feb 2025 | 5,263 | 210,717 (0%) | 0% | 8.1 | 42,472 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 103,698 | 103,698 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 64,293 | 215,980 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 02 Jan 2025 | 13,891 | 151,687 (0%) | 0% | 7.7 | 107,377 | Common Stock |
| Regenxbio Inc | Stephen Pakola | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 58,386 | 165,578 (0%) | 0% | 0 | Common Stock |